A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

Pts must have histologic/cytologically-confirmed limited SCLC or diagnosis based on sputum w/confirmation by independent pathology review; Pts must have evidence of measurable or non-measurable disease by CT, MRI or X-ray; Pts may have had surgery >/= 2 weeks prior to registration and recovered from all toxicities; Pts must have confirmation that any abnormal scan findings are not metastatic disease; Pts must have ANC >/= 1, 500, PLTS >/= 100,000, FEV1 and DLCO obtained, Zubrod PS 0-1, CrCl >/= 50 cc/min, if calculated CrCl used, serum creatinine must be < 1.5 mg/dl, serum bilirubin </= 1.5 x IULN and SGOT/SGPT </= 2 x IULN; Pts must be >/= 18 yrs old; Pts must not have other prior malignancy except: treated basal cell or squamous cell skin ca, in situ cervical ca, Stage I or II ca in complete remission or disease-free from any ca for 5 yrs; Pts must not have brain mets; Pts must not have malignant pericardial or pleural effusions or known symptomatic coronary artery disease or prior MI; Pts must not have had prior chemo, biologic therapy for SCLC or thoracic or neck RT for any reason; pts who are hearing-impaired must be willing to accept further worsening; Pts must not have >/= Grade 1 symptomatic neuropathy-sensory; Pts must not be pregnant or nursing; Pts of reproductive potential must agree to use of effective contraceptive method; Institutions must have IRB approval of S9925 and pts must be offered participation on S9925.